You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy
SBC: MOONLIGHT THERAPEUTICS, INC. Topic: NIAIDThe following contains proprietary/privileged information that Moonlight Therapeutics requests not be released to persons outside the government, except for purposes of review and evaluation Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within theSkin) patch for the Treatment of Peanut Allergy Food allergies affect 30 million people in the USA and 17 million in ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Low-Cost Wearable Connected Health Device for Monitoring Environmental Pollution Triggers of Asthma in Communities with Health Disparities
SBC: WI-SENSE LLC Topic: NHLBIProject Abstract Asthma affects 25 million Americans, and chronic obstructive pulmonary disease (COPD) affects 16 million,together costing 130 billion USD annually to the US healthcare system. Asthma is more prevalent in AfricanAmerican population (10.6%) than white population (7.7%). Poverty level has an impact as well, with twice asmuch asthma incidence in people below 100% of the poverty thresh ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Enhanced renal dialysis membrane performance using lipocalin modified substrates
SBC: HIBAR Microsciences, LLC Topic: 400PROJECT SUMMARY: It is estimated that more than 30 million American adults have chronic kidney disease (CKD), with nearly 800,000 living with end-stage renal disease (ESRD). People with chronic diseases such as diabetes, high blood pressure, and heart disease are at a higher risk for CKD. Because their kidneys no longer function, individuals with ESRD often rely on hemodialysis to remove waste fro ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Recognition of O-GlcNAc Modified Proteins Using Site-Specific Antibodies
SBC: GLYCOSCIENTIFIC, L.L.C. Topic: NHLBIPulmonary arterial hypertension (PAH) is a progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery) for no apparent reason. PAH is a disease of pulmonary vascular endothelial dysfunction with nitric oxide (NO) deficiency and dysregulated glucose metabolism/utilization. It is a heterogeneous disorder likely to be comprised of overlappi ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Integration of non-invasive deep tissue microwave thermometry in the VectRx hyperthermia device in a transgenic liver tumor pig model
SBC: NeoTherma Oncology Inc. Topic: 102Project Summary/Abstract NeoTherma Oncology (NTO/www.neothermaoncology.com) has developed a novel non-invasive medical device that delivers mild hyperthermia (HT) loco-regionally as adjuvant therapy to standard of care treatment of abdominal deep-seated tumors. The VectRx™ device, designated “Breakthrough” by the FDA, has demonstrated its ability to safely heat abdominal organs (pancreas, li ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
An online professional development course to train CHWs to provide oral health outreach to low-income Black guardians
SBC: KDH Research & Communication, Inc. Topic: WKDH Research and Communication (KDHRC) submits this Phase II Small Business Innovation Research (SBIR) application to expand and fully evaluate Guardians Receiving Information through Navigators (GRIN). GRIN is a culturally competent, online professional development course to prepare community health workers (CHWs) to provide oral health outreach to low- income Black parents/guardians (henceforth ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing a PIV5-based human metapneumovirus (HMPV) vaccine
SBC: CYANVAC LLC Topic: NIAIDABSTRACT In this Phase I SBIR application, we propose to develop an intranasal, parainfluenza virus 5 (PIV5)-based human metapneumovirus (HMPV) vaccine. HMPV is one of the leading causes of acute respiratory infections (ARIs) in children, immunocompromised individuals, and the elderly. Illness ranges from asymptomatic infection to severe bronchiolitis and pneumonia, with 90-100% of children infect ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Guidewire Design and Coating for Adenosine Delivery
SBC: ADENOPAINT LLC Topic: NHLBICoronary artery disease (CAD) effects 14 million Americans resulting in approximately 900,000 myocardial infarction’s (MI) and 650,000 deaths annually. Percutaneous intervention (PCI) is the most frequently performed procedure to treat CAD. Microvascular obstruction (MVO) and “no reflow phenomenon” (NRF) are major barriers that preclude optimal outcomes and are independent risk factors for m ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Design and synthesis of a next generation glycobiology toolbox for cell surface labeling
SBC: CHEMILY, LLC Topic: 300The cell membrane is the interface by which a cell interacts and communicates with its surroundings, including nearby cells, proteins, and antibodies. Membranes of healthy cells are often modified in diseased states, providing an external means to distinguish between morphologically similar cells. Often, diseased cells display modified carbohydrates and glycans on their cell membranes. Recent deve ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma
SBC: OncoSpherix, Inc. Topic: 102Summary:The goal of this Phase II SBIR is to advance OncoSpherix’s HIF-1 inhibitor, 64B, as part of combination therapy for metastatic and high-risk uveal melanoma (UM), the most prevalent primary eye cancer in adults. 64B is a small molecule therapeutic that inhibits HIF function by disrupting the recruitment of the transcriptional co- factor, p300/CBP, while leaving intact p300/CBP’s ability ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health